Advertisements

Cel-Sci Corporation ($0.001 Par Value) (CVM) Stock Quote

Detailed Quote for Cel-Sci Corporation ($0.001 Par Value) (CVM)
$ 0.095   -0.0037 (-3.75%) Volume: 1.48m 4:02 PM EST Feb 24, 2017
After Hours:  $ 0.0959   0.0009 (+0.95%) Volume: 800 5:57 PM EST Feb 24, 2017
Today 5d 1m 3m 1y more
Last Price
0.095
Change $
0.0037
Change %
3.75%
Tick
  
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
0.095
High
0.0969
Low
0.092
Prev Close
0.0987
Last Trade
02/24/17
Volume
1.48m
52 Wk Hi
0.660000026
52 Wk Low
0.059999998
Market Cap
18.14m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
190,965,450
EPS (TTM)
-0.090000003
PE Ratio
N/A
Exchange
NYSE MKT
News and Media for Cel-Sci Corporation ($0.001 Par Value) (CVM)
Sector News | Topic News
News for Cel-Sci Corporation ($0.001 Par Value) (CVM)
Tue, Feb 21, 2017
8:45 AM CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference - Business Wire
Fri, Feb 17, 2017
8:30 AM CEL-SCI Announces $1.0 Million Registered Direct Offering - Business Wire
Thu, Feb 09, 2017
5:36 PM Cel-Sci reports FQ1 results - SeekingAlpha
5:15 PM CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results - Business Wire
Tue, Dec 20, 2016
5:58 PM CEL-SCI Announces Closing of Public Offering and Receives Audit Opinion with Going Concern Explanation - Business Wire
Wed, Dec 14, 2016
5:49 PM Cel-Sci reports FY results - SeekingAlpha
5:36 PM CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments - Business Wire
Fri, Dec 09, 2016
6:00 PM CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan - Business Wire
Fri, Dec 02, 2016
7:36 AM CEL-SCI prices equity offering - SeekingAlpha
7:00 AM CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants - Business Wire
Thu, Dec 01, 2016
4:01 PM CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants - Business Wire
Mon, Nov 21, 2016
10:52 AM CEL-SCI submits response to FDA's partial clinical hold of Multikine study in head and neck cancer - SeekingAlpha
8:30 AM CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial - Business Wire
Mon, Nov 14, 2016
9:00 AM CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating Rheumatoid Arthritis - Business Wire
Fri, Oct 21, 2016
8:00 AM CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial - Business Wire
Tue, Sep 27, 2016
7:22 AM FDA places CEL-SCI's Multikine study in head and neck cancer on clinical hold; shares off 13% premarket - SeekingAlpha
Mon, Sep 26, 2016
11:03 PM CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study - Business Wire
Tue, Sep 06, 2016
8:30 AM CEL-SCI Announces Resignation of its Founder for Health Reasons - Business Wire
Fri, Sep 02, 2016
9:00 AM CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial - Business Wire
Mon, Aug 29, 2016
9:00 AM CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering - Business Wire
More News for CVM >>

Tags for Cel-Sci Corporation ($0.001 Par Value)

Research stocks or mutual funds related to Cel-Sci Corporation ($0.001 Par Value) by keywords or tags. Find companies that have a similar focus to CVM. The keywords below have been associated to CVM by either user submission or electronic means.

biotech research clinical trial enrollment clinical research trial clinical research software laboratory research arthritis causes corporate financial clinical cost disney annual report pharmaceutical study research institutes clinical research consulting Medical Laboratories (8071) annual report asthma clinical trial Biological Products phase iii clinical trials financial report cra clinical research research clinical research technology research phase 3 clinical trials clinical trials manager fda clinical trial medical research immunology reactive arthritis biotechnology research what causes arthritis physician clinical trials Drugs comfort research annual report of company corporate annual report 3m annual report clinical trials recruitment clinical trials conference clinical metabolic research clinical study agreements clinical data Healthcare clinical trial publication clinical research network monitoring clinical research financial statement software clinical research nurse Except Diagnostic Substances (2836) financial statement